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Background: Mortality in patients with myelodysplastic syndromes (MDS) is high, and patients are likely to require
hospitalizations, emergency department (ED) visits, and transfusions. The relationships between these events and the
MDS complications of anemia, neutropenia, and thrombocytopenia are not well understood.
Patients and methods: A total of 1864 patients registered in the United States’ Surveillance Epidemiology and End
Results (SEER) program and aged ‡66 years old when diagnosed with MDS in 2001 or 2002 were included. Medicare
claims were used to identify MDS complications and utilization (hospitalizations, ED visits, and transfusions) until death
or the end of 2005. Mortality was based on SEER data. Kaplan–Meier incidence rates were estimated and
multivariable Cox models were used to study the association between complications and outcomes.
Results: The 3-year incidence of anemia, neutropenia, and thrombocytopenia was 81%, 25%, and 41%, and the
incidence of hospitalization, ED visit, and transfusion was 62%, 42%, and 45%, respectively. Median survival time was
22 months. Cytopenia complications were signiﬁcantly associated with each of these outcomes.
Conclusions: All types of cytopenia are common among patients with MDS and are risk factors for high
rates of health care utilization and mortality. Management of the complications of MDS may improve patient
outcomes.
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introduction
The myelodysplastic syndromes (MDS) are a heterogeneous
group of myeloid clonal hematopoietic disorders in which
immature blood cells die either in the bone marrow or soon
after they enter into circulation. The majority of MDS cases are
not associated with known exposures (de novo cases) although
genotoxic exposures, such as chemotherapy, may also be
associated with its development [1]. Depending on the subtype
of de novo MDS, median survival estimates currently range
from 5 months to 6 years if left untreated [2]. MDS
primarily affects the older population, and incidence has been
shown to increase with age [3–5]. In addition, there is some
evidence that MDS incidence rates may be increasing in the
population [6]. The incidence of MDS could continue to rise
due to the aging of the population, improvements in geriatric
medicine, physician awareness, and other factors [6, 7].
Clinical complications of MDS can include one or more
types of peripheral cytopenia (anemia, neutropenia, and
thrombocytopenia), which can in turn cause increased
susceptibility to serious infections, bleeding, and other adverse
events [8]. Also, patients with MDS are at increased risk for
developing acute myeloid leukemia (AML), a cancer with
a 95% 5-year mortality rate in patients ‡65 years [6].
However, more patients with MDS die of consequences of
MDS than from AML [9]. The cytopenias can each lead to
hospitalizations, emergency department (ED) visits, and
transfusions over the course of the disease. However, the
rates of health care utilization in patients with MDS are
unknown, and the association between the key complications of
MDS on rates of health care utilization and mortality is also
unknown.
Characterizing the relationship between the key
complications of MDS and health care utilization and mortality
could lead to better understanding of the burden of MDS on
the patient and health care system. The ﬁrst objective of this
study was to estimate the prevalence and incidence of anemia,
neutropenia, and thrombocytopenia in a population-based
sample of older patients with MDS. The second was to
estimate the incidence rates of hospitalization, ED visits,
transfusions, and mortality in these patients. The ﬁnal objective
was to assess the independent association of each cytopenia on
outcomes.
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data source
We used the National Cancer Institute (NCI) SEER–Medicare linked
database to identify patients diagnosed with MDS [10]. The SEER database
is a population-based registry that tracks information about cancer patients
from certain geographically deﬁned areas in the United States. The database
includes patient demographics, the dates and other characteristics of
primary and subsequent cancer diagnoses, and follow-up on vital status.
During the period from which our patients were identiﬁed, 17 geographical
areas representing 26% of the USA population were covered by the SEER
registry [11].
The Medicare data linked to the SEER database include Parts A and B
claims for hospital, physician, and outpatient claims (including hospital
outpatient clinics). The NCI reports that 93% of patients aged ‡65 years
in the SEER ﬁles are matched to the Medicare enrollment ﬁles [12].
patient eligibility
We selected our study population from individuals residing in areas
captured by the SEER registry who were diagnosed with MDS from January
2001 to December 2002 and who did not have any previously recorded
cancer diagnoses. We identiﬁed MDS using International Classiﬁcation of
Diseases for Oncology, 3rd edition, histology codes in the SEER registry
which closely correspond to the classiﬁcation system proposed by the
World Health Organization [13–15]. These included the following seven
codes: 9980 [refractory anemia (RA)]; 9982 (RA with sideroblasts); 9983
[refractory anemia with excess blasts (RAEB)]; 9985 (refractory cytopenia
with multi-lineage dysplasia); 9986 (5q deletion syndrome); 9987 (therapy-
related MDS); and 9989 [MDS, not otherwise speciﬁed (NOS)].
The Medicare data linked to our patient population included claims from
1 January 1997 until 31 December 2005. Of all 3025 patients diagnosed with
MDS in 2001 or 2002, 326 were excluded for being under age 66, 130
additional patients were excluded for not having both Parts A and B
Medicare claims continuously for at least one full year before MDS
diagnosis, and 554 were excluded for having Health Maintenance
Organization (HMO) coverage in the year before MDS diagnosis. These
exclusions were made in order to accurately identify prevalent symptoms
and comorbid conditions at the time of diagnosis. In addition, we excluded
151 patients who died in the month of their diagnosis or who were missing
the month of diagnosis.
patient characteristics
The date of MDS diagnosis, age at diagnosis, gender, race/ethnicity,
socioeconomic characteristics, and date of death were all taken from the
SEER database. Age at diagnosis was categorized as 66–69, 70–74, 75–79,
and ‡80 years old. Race and ethnicity were deﬁned using the SEER recoded
race variable which categorizes patients as white, black, Hispanic, and other
(which consists predominately of American Indian/Native Alaskan, Native
Hawaiian or Other Paciﬁc Islander, and Asian). Socioeconomic
characteristics included information about college education, poverty, and
population density in the census tract where patients were residing at the
time of diagnosis [10].
A comorbidity score, based on the Charlson Comorbidity Index [16]
with adaptations for cancer patients suggested by Deyo and Romano [17,
18], was calculated using Medicare claims data from the 12 months before
the MDS diagnosis date according to an algorithm supplied by the NCI
[19]. Comorbidity scores were categorized into 0, 1, 2, and ‡3 conditions.
MDS complications and outcomes
We identiﬁed prevalent anemia, neutropenia, and thrombocytopenia at the
time of MDS diagnosis using Medicare claims from the 6 months before
and during the month of MDS diagnosis (the prevalence period). Incident
cytopenia cases were identiﬁed from the month after MDS diagnosis to the
end of observation (the incidence period). Qualifying Medicare claims
included International Classiﬁcation of Diseases, 9th Edition, Clinical
Modiﬁcation (ICD-9-CM) diagnosis and procedure codes, revenue center
codes, and Healthcare Common Procedure Coding System (HCPCS) codes
(see Appendix, available at Annals of Oncology online).
Claims likely to be made only for testing purposes were excluded from
prevalent and incident cytopenia case counts. At least one inpatient or
outpatient code was required to identify cytopenia. If there was an
outpatient code but no inpatient code in the prevalence or incidence
period, a second outpatient code was required at least 30 days after the ﬁrst
one occurred for conﬁrmation. All inpatient and outpatient diagnosis codes
for cytopenia were included in this algorithm. Procedure codes were
included in cytopenia deﬁnitions if they indicated transfusion therapy [red
blood cell (RBC) for anemia and platelet for thrombocytopenia] or
chemotherapy (darbepoetin or epoetin alfa for anemia, ﬁlgrastim or
pegﬁlgrastim for neutropenia, and oprelvekin for thrombocytopenia).
Hospitalizations, ED visits, and transfusions were also identiﬁed using
Medicare claims. Both short- and long-term hospital stays were counted as
hospitalizations, excluding ED visits, outpatient hospital visits, and skilled
nursing facility stays. MDS-speciﬁc hospitalizations were deﬁned as those
associated with bleeding or fever. They were based on Diagnosis-Related
Group (DRG) and primary diagnosis codes, or secondary diagnosis codes if
the primary code was for MDS. ED visits were determined from physician
claims for care given in any ED. ICD-9-CM procedure codes, HCPCS, and
revenue center codes were used to identify the ﬁrst of any type of
transfusion, as well as the ﬁrst RBC transfusion, platelet transfusion, or
other type of transfusion. Death dates and causes of death were determined
using the SEER data.
Claims were searched from the end of the month of MDS diagnosis until
the ﬁrst occurrence of the complication or the end of observation. The end
of the observation period was the patients’ date of death, the end of
Medicare Part A or B coverage, the beginning of HMO coverage,
a new non-AML cancer diagnosis, or 31 December 2005 (whichever
came ﬁrst).
statistical analyses
We calculated the 3-month and 3-year cumulative incidence rates and
corresponding 95% conﬁdence intervals (CIs) using the Kaplan–Meier
(KM) method and plotted the KM cumulative incidence of each
complication and outcome over the study period. Patients diagnosed with
a cytopenia during the prevalence period were excluded from cytopenia
incidence rate calculations.
Cox regression models were used to calculate multivariable-adjusted
hazard ratios (HRs) and 95% CIs for all utilization outcomes
(hospitalizations, ED visits, and transfusions). All models included the
patients’ age category, gender, race/ethnicity, NCI comorbidity score, year
of MDS diagnosis, and their census tract’s education, poverty, and
population density. In addition, all models included time-varying
covariates of prevalent or incident anemia, neutropenia, and
thrombocytopenia. Prevalent cytopenia cases were incorporated into time-
varying cytopenia covariates by indicating their presence during the entire
timeline. Transfusions were included in the deﬁnition of cytopenia for all
models except those with transfusion outcomes. The frequency and percent
of hospitalizations for events other than bleeding and fever were reported.
Multivariable Cox models adjusted for baseline characteristics were also
used to determine whether cytopenia, hospitalizations, and ED visits were
associated with risk of death. In addition, the frequency and percent of
the most common SEER-coded causes of death and of AML, other
leukemia, and other malignancies were reported. SEER had no speciﬁc code
for MDS as the cause of death.
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histology codes for RA, RA with sideroblasts, and RAEB in addition to
claims data to identify prevalent anemia. In addition, we tested the impact
of adjusting our models for MDS subtypes (all histology codes). Finally,
analyses were repeated after extending the prevalence period for identifying
cytopenia claims to a full year before diagnosis. Analyses were conducted
using Stata 10.1 for Windows (Stata Corporation, College Station, TX). All
P values reported are two sided.
results
patient characteristics
The ﬁnal population included 1864 patients whose mean age at
the time of diagnosis was 78.8 years; 47% were female and 85%
were white. The mean number of comorbid conditions at the
time of diagnosis was 1.2, with a range of 0–10. Forty-four
percent were diagnosed with the RA, RA with sideroblast, or
RAEB subtype. Eighty-ﬁve percent had been diagnosed with
prevalent anemia, 13% with neutropenia, and 23% with
thrombocytopenia by the time of MDS diagnosis. See Table 1
for additional baseline characteristics.
MDS complications and health care utilization
The incidence rates of anemia, neutropenia, and
thrombocytopenia for patients not diagnosed with these
complications by the time of MDS diagnosis are presented in
Table 2. KM incidence plots for these complications over the
study period are shown in Figure 1. Incidence rates for
hospitalizations, ED visits, and transfusions are presented in
Table 3, and cumulative incidence plots over the study period
are shown in Figure 2.
In multivariable Cox models, all types of cytopenia were
independently associated with higher utilization. There was
a signiﬁcantly higher risk of hospitalization for patients with
cytopenia (anemia HR = 1.80, 95% CI 1.61–2.01; neutropenia
HR = 1.59, 95% CI 1.34–1.87; thrombocytopenia HR = 1.80,
95% CI 1.59–2.04), ED visits (anemia HR = 1.96, 95% CI 1.72–
2.24; neutropenia HR = 1.30, 95% CI 1.10–1.54;
thrombocytopenia HR = 1.76, 95% CI 1.55–1.99), and
transfusions (anemia HR = 2.28, 95% CI 2.01–2.59;
neutropenia HR = 1.94, 95% CI 1.64–2.30; thrombocytopenia
HR = 1.52, 95% CI 1.31–1.83). Other independently associated
predictors (P < 0.05) of hospitalization and ED visits included
age >80 years versus 66–69 years old, rural versus big
metropolitan census tract areas, and one or more versus no
comorbidities. Other independently associated predictors of
transfusions included black versus white race and more than
three versus no comorbidities (Figure 3). Thrombocytopenia
was the strongest independent predictor of being hospitalized
for a bleeding event (HR = 3.34, 95% CI 2.81–3.97).
Neutropenia was the strongest predictor of being hospitalized
for a fever (HR = 3.69, 95% CI 2.97–4.58).
Among the patients hospitalized during our study, 8% were
ﬁrst hospitalized for a bleeding event and 5% were ﬁrst
hospitalized for a fever. Of the remaining hospitalized patients,
the most common reasons according to DRG codes were
lymphoma and non-acute leukemia with complications (DRG
code 403, 17%), RBC disorders (DRG code 395, 12%), simple
pneumonia and pleurisy with complications (DRG code 89,
5%), and heart failure and shock (DRG code 127, 5%).
MDS complications and mortality
Incidence rates for death are presented in Table 3, and
cumulative incidence over the entire study period is shown in
Figure 2. Adjusting for baseline characteristics, those
diagnosed with prevalent or incident cytopenia were
Table 1. Baseline characteristics of patients diagnosed with MDS in the
United States, 2001–2002
Baseline characteristics Level n (%)
Age 66–69 184 (10)
70–74 372 (20)
75–79 444 (24)
‡80 864 (46)
Gender Male 986 (53)
Female 878 (47)
Race/ethnicity White 1591 (85)
Black 120 (6)
Hispanic 81 (4)
Other 72 (4)
NCI comorbidity score 0 808 (45)
1 468 (26)
2 259 (14)
‡3 275 (15)
Percentage of 25+ year-olds
in census tract with some
college
0–24 1027 (56)
‡25 814 (44)
Percent living in poverty in
census tract
<5 555 (30)
5–9 538 (29)
‡10 748 (41)
Population density Big metropolitan 1103 (59)
Metropolitan 470 (25)
Urban 89 (5)
Less urban/rural 202 (11)
Year of diagnosis 2001 926 (50)
2002 938 (50)
MDS subtype
a Refractory anemia 353 (19)
Refractory anemia with
sideroblasts
229 (12)
Refractory anemia with
excess blasts
240 (13)
Refractory cytopenia with
multi-lineage dysplasia
57 (3)
5q deletion syndrome 40 (2)
Therapy related 24 (1)
MDS not otherwise speciﬁed 921 (49)
Prevalent anemia 1589 (85)
Prevalent neutropenia 239 (13)
Prevalent thrombocytopenia 425 (23)
Transfusions received Any type 488 (26)
Red blood cell 470 (25)
Platelet 46 (2)
Other/unknown 243 (13)
aBased on the International Classiﬁcation of Diseases for Oncology, 3rd
edition, histology codes recommended by the World Health Organization.
MDS, myelodysplastic syndromes; NCI, National Cancer Institute.
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HR = 2.20, 95% CI 1.76–2.75; neutropenia HR = 1.60, 95% CI
1.40–1.83; and thrombocytopenia HR = 2.73, 95% CI 2.43–
3.07). Other independently associated predictors (P < 0.05) of
mortality included female gender and black versus white race
(Figure 3).
Table 2. Incidence of key complications in patients diagnosed with MDS in the United States, 2001–2002
Complication
a Months to ﬁrst occurrence 3-Month cumulative incidence
b 3-Year cumulative incidence
b
Median IQR % 95% CI % 95% CI
Anemia 5 2–6 28 23–33 81 76–86
Neutropenia 16 5–39 5 4–6 25 22–28
Thrombocytopenia 15 5–39 9 8–11 41 38–44
aAmong patients without the complication by the time of MDS diagnosis.
bEstimated by Kaplan–Meier method.
MDS, myelodysplastic syndromes; CI, conﬁdence interval; IQR, interquartile range.
Figure 1. Cumulative incidence of anemia, neutropenia, and thrombocytopenia after diagnosis in patients diagnosed with myelodysplastic syndromes in
the United States, 2001–2002.
Table 3. Incidence of health care utilization and mortality outcomes in patients diagnosed with myelodysplastic syndromes in the United States,
2001–2002
Outcome event Months to ﬁrst occurrence 3-Month cumulative incidence
a 3-Year cumulative incidence
a
Median IQR % 95% CI % 95% CI
Hospitalization
Any reason 1 0.3–8 62 60–64 91 90–92
Bleeding 14 4–37 12 11–14 41 38–44
Fever 16 5–38 9 7–10 30 27–33
ED visit 4 1–13 42 39–44 87 85–88
Transfusion
Any type 3 1–20 45 43–47 75 72–77
Red blood cell 4 1–21 44 41–46 74 71–76
Platelet 16 5–39 7 6–9 29 27–32
Other/unknown 6 2–28 23 21–25 57 54–60
Death 22 8–42 11 10–12 64 62–66
aEstimated by Kaplan–Meier method.
CI, conﬁdence interval; ED, emergency department; IQR, interquartile range.
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and time-varying covariates for cytopenia and utilization,
hospitalization for any reason was the strongest predictor of
death (HR = 6.54, 95% CI 4.70–9.11), followed by incident
thrombocytopenia (HR = 2.27, 95% CI 2.02–2.56) and ED
visits (HR = 2.09, 95% CI 1.77–2.47).
The most common speciﬁc causes of death according to
SEER were malignant cancer (35%), in situ, benign, or
unknown behavior neoplasm (25%), and diseases of the heart
(15%). Ten percent died of AML, 9% died of another form of
leukemia, and 16% died of other malignancies. Nonspeciﬁc or
unknown causes of death accounted for 19% of all deaths.
Figure 2. Incidence of hospitalization (from top to bottom: any reason, bleeding event, fever), emergency department (ED) visits, transfusions (from top to
bottom: any type, red blood cell, other/unknown, platelet), and death after diagnosis in patients diagnosed with myelodysplastic syndromes in the United
States, 2001–2002.
Figure 3. Multivariable analysis of the characteristics and complications associated with health care utilization and mortality in patients diagnosed with
myelodysplastic syndromes in the United States, 2001–2002.
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The prevalence of anemia at diagnosis would have been 91% if
the SEER histology codes for RA, RA with sideroblasts, and
RAEB had been included in the deﬁnition. However, the
direction and signiﬁcance of the associations between incident
cytopenia and the outcomes remained similar after adding
these histology codes to the deﬁnition of prevalent anemia
(results not shown). Adjusting the models for MDS subtype
and extending the period for identifying all prevalent
cytopenias to a full year before diagnosis also resulted in similar
ﬁndings.
conclusions
This study conﬁrms ﬁndings from previous studies in addition
to adding important new information about the natural history
of MDS with regard to health care utilization and mortality.
Our cohort had a distribution of MDS subtypes and 3-year
mortality rates similar to those found in other recent studies of
elderly patients with MDS [20, 21]. We also found that elderly
patients are frequently diagnosed with anemia, neutropenia,
and thrombocytopenia in inpatient and outpatient settings
before they are diagnosed with MDS. We describe for the ﬁrst
time cytopenia incidence rates in patients with MDS for whom
cytopenia was not previously diagnosed. In addition, we
describe in detail how prevalent and incident cytopenia
complications are associated with high health care utilization
rates and mortality.
A large proportion of the elderly patients with MDS in this
study were either hospitalized (62%) or went to an ED (42%)
within 3 months of diagnosis. Bleeding and fevers were often
listed as the primary reasons for these hospitalizations. We
chose to study these reasons for hospitalization because they are
speciﬁc symptoms that may be attributed to thrombocytopenia
and neutropenia, respectively, and are known to be risk factors
for death among patients with MDS [22, 23]. There are, of
course, other possible MDS-related reasons for hospitalization,
ED visits, and death. Pneumonia and pleurisy or cardiac failure
are also likely to be attributable to the MDS, for example.
Without a healthy comparison cohort of similar age and
without more speciﬁc information (such as autopsy data), it is
impossible to identify the mechanism or excess risk that MDS
conferred on these cause-speciﬁc events.
Though the goal of the present study was to estimate event
rates and associations within the MDS population,
comparisons with a non-cancer control population would be
valuable. While this was beyond the current scope of this
research, a recent study compared patients with MDS with
other Medicare beneﬁciaries and found that MDS and
transfusion dependency are associated with increased risk of
comorbidity and mortality [24]. Our ﬁnding that
thrombocytopenia and neutropenia were the strongest
respective independent predictors of hospitalization for
bleeding and fever also provides some support for MDS being
the underlying cause of these particular events.
A transfusion of any kind occurred in the majority (three-
quarters) of our patients within 3 years. Transfusions are still
a common form of supportive therapy and will most likely
continue to be used for patient management [25–27]. Although
pharmacotherapy combined with transfusion therapy has been
the preferred method for treating MDS for some time,
transfusion dependency is still a common occurrence and is
a strong predictor of survival and progression to AML [28, 29].
Our results show an association between all types of
prevalent and incident cytopenia and mortality, independent of
patient demographics, the number of comorbidities at the time
of MDS diagnosis, and other factors. One explanation for this is
that the complications of these cytopenias, particularly bleeding
and infections, may increase the risk of death. Other studies
have also reported that severe bleeding events and infections
account for a large portion MDS-related deaths [22]. In this
study, we were not able to estimate how many died of bleeding
or infection, but we know that only 10% died of AML, 25%
died of other types of leukemia or cancers, and 25% died of an
‘in situ, benign, or unknown behavior neoplasm’. Because there
is no speciﬁc code for MDS as the cause of death, we cannot
determine this quantitatively.
It is possible that many of the remaining deaths were due to
unrelated events or comorbidity. Comorbidity has been shown
to be a signiﬁcant and independent predictor of mortality in
elderly patients with MDS [30]. Regardless of cause, over half of
our cohort of patients with MDS (with an average age of almost
80 years old) died in <2 years. In contrast, the average life
expectancy for 80-year-olds in the USA population in 2002 was
9 years [31]. More speciﬁc analyses are needed to more
precisely estimate the excess risk associated with MDS, but it is
clearly substantial.
One limitation of this study is that we relied on
administrative claims data to identify prevalent and incident
cytopenias, which may have resulted in an underestimate of
these complications. Although other methods would have been
possible and valid (such as using histology codes to identify
anemia patients), our conclusions were not sensitive to any of
the alternate deﬁnitions we tested. In addition, our cohort
consisted of patients aged ‡66 years who were enrolled in non-
HMO Medicare Parts A and B for at least 1 year before MDS
diagnosis and throughout follow-up. Thus, our ﬁndings may
not accurately reﬂect what happens with younger and privately
insured MDS patients.
Other limitations are related primarily to the fact that we
used patients diagnosed and reported to SEER in 2001 and
2002. MDS became reportable to SEER in 2001, and MDS
incidence rates increased in the USA population in the years
following, suggesting a possible change in capture rates due to
reporting issues [20]. Although we cannot determine how
much inﬂuence this has had on our cohort, we had good
representation of patients from different sociodemographic
subgroups, and we adjusted for these characteristics in all of
our models. Reporting issues may be related to SEER region
and differing methods for case ﬁnding [32], but these are likely
to be adequately accounted for through sociodemographic
adjustments. Also related to the capture period is the fact that
we did not have access to data on the percentage of myeloblasts
or other morphological and genetic characteristics of our
patients. Thus, we were limited in our ability to identify distinct
subtypes of MDS. Nearly half of the patients in our study
population were diagnosed with a nonspeciﬁc subtype of MDS
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This group likely represents multiple subtypes that were not yet
differentiable in 2001 or 2002, at least by data available to
SEER. Despite many efforts to standardize the criteria for
classifying subtypes using detailed laboratory ﬁndings, this still
poses a major challenge to clinicians and researchers [33, 34].
Despite these limitations, ﬁndings from this and other recent
epidemiological studies can serve as important comparison
data for future studies. It should also be noted that the fact that
our cohort was diagnosed in 2001 and 2002 and followed
through 2005 means that our study period predates the
approval or wide use of many newer chemotherapies.
This ensures that we were able to capture the natural history
of disease and avoid confounding from therapies that might
cause or exacerbate certain cytopenias, especially
thrombocytopenia [22].
Quantifying the effect of incident complications on
outcomes among patients with MDS emphasizes the
importance of preventing these complications where possible
and managing them effectively when they occur. They have
signiﬁcant effects on both individual patients’ outcomes and
the health care system.
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